Skip to main content
Fig. 2 | Stem Cell Research & Therapy

Fig. 2

From: Melatonin treatment improves human umbilical cord mesenchymal stem cell therapy in a mouse model of type II diabetes mellitus via the PI3K/AKT signaling pathway

Fig. 2

Melatonin upregulates MT1 and MT2 expression. a Cell morphology of hUC-MSCs. b Semiquantitative RT–PCR analysis of MT1 and MT2 expression in hUC-MSCs treated with melatonin. c Western blot analysis of MT1 and MT2 expression levels in hUC-MSCs treated with melatonin. GAPDH was used as a loading control. d The relative levels of MT1 and MT2 in the UCMSC and UCMSC/Mel groups. e Cell immunofluorescence MT1 and MT2 expression in untreated cells (UCMSCs) and melatonin cocultured hUC-MSCs (UCMSCs/Mel). f EdU staining in UCMSCs and UCMSCs/Mel. g Cell proliferation rate analyzed by EdU staining. h Cell growth curve of untreated cells (UCMSCs) and melatonin-cocultured hUC-MSCs (UCMSCs/Mel). MT1 (melatonin receptor 1); MT2 (melatonin receptor 2); UCMSC (hUC-MSCs); Mel (melatonin). Data are mean ± SD; *P < 0.05; **P < 0.01; ***P < 0.001.

Back to article page